Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-08-13), Kingworld Medicines Group's Beta is 0.2004.
Kingworld Medicines Group (HKSE:01110) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kingworld Medicines Group Beta Competitor Comparison
For the Pharmaceutical Retailers subindustry, Kingworld Medicines Group's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kingworld Medicines Group Beta vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Kingworld Medicines Group's Beta distribution charts can be found below:
* The bar in red indicates where Kingworld Medicines Group's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Kingworld Medicines Group (HKSE:01110) has a Beta of 0.2004 as of Aug. 13, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Kingworld Medicines Group and its competitors.
Is Kingworld Medicines Group's Beta too high?
Kingworld Medicines Group's current Beta is 0.2004. Overall, Kingworld Medicines Group has a GF Score™ of 43/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kingworld Medicines Group's Beta compare to competitors?
Kingworld Medicines Group's Beta of 0.2004 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Healthcare Providers & Services company?
A good Beta depends on the Healthcare Providers & Services industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Kingworld Medicines Group and its competitors. Kingworld Medicines Group's current Beta is 0.2004. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kingworld Medicines Group stock overvalued right now?
Based on GuruFocus' analysis, Kingworld Medicines Group (HKSE:01110) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.50, compared to a current price of HK$0.48 — trading 5% below its estimated fair value. The current Beta is 0.2004. Kingworld Medicines Group's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Kingworld Medicines Group (HKSE:01110), the current Beta is 0.2004 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kingworld Medicines Group (HKSE:01110) Overvalued in 2026?
Based on GuruFocus' analysis, Kingworld Medicines Group stock appears to be undervalued.
The current stock price of HK$0.48 is trading 5% below its estimated GF Value™ of HK$0.50.
GuruFocus considers Kingworld Medicines Group to be Fairly Valued.
Key valuation signals for HKSE:01110:
Beta: 0.2004
GF Value™: HK$0.50 vs. price of HK$0.48 (5% below fair value)
No single metric tells the full story. See the HKSE:01110 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kingworld Medicines Group Ltd is engaged in the Distribution of pharmaceutical and healthcare products, such as branded imported pharmaceutical and healthcare products in Hong Kong and the PRC, and Manufacturing and sales of electrotherapeutic and physiotherapeutic devices and general medical examination devices carried out in the PRC. It derives the majority of its revenue from the Distribution sales of the pharmaceutical and healthcare products segment.
43GF Score
Get the complete analysis for HKSE:01110
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01110 has been successfully added to your 
